Experienced in Dysembryoplastic Neuroepithelial Tumors (DNET)

Dr. Wenyin J. Shi

Radiation Oncology
Jefferson University Physicians
111 S 11th St, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Jefferson University Physicians
111 S 11th St, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Wenyin Shi is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Shi is rated as an Experienced provider by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). His top areas of expertise are Astrocytoma, Glioblastoma, Mycosis Fungoides, Brain Tumor, and Gamma Knife Radiosurgery.

His clinical research consists of co-authoring 166 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in PA
Hospital Affiliations
Jefferson Stratford Hospital
Thomas Jefferson University Hospital
Wills Eye Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

JEFFERSON UNIVERSITY PHYSICIANS
111 S 11th St, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Radiation, Other, Procedure
Study Phase: Phase 1
A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients
A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients
Enrollment Status: Completed
Publish Date: June 06, 2025
Intervention Type: Behavioral, Radiation, Procedure, Other
Study Phase: Not Applicable
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Other
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2025
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Biological, Procedure, Radiation
Study Phase: Phase 2
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 1
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Device
Study Phase: Phase 2
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Radiation, Procedure, Other
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2024
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
View 13 Less Clinical Trials

166 Total Publications

Contrast enhancement, G-CIMP subtype, and CDKN2A/B homozygous deletion in IDH-mutant astrocytoma.
Contrast enhancement, G-CIMP subtype, and CDKN2A/B homozygous deletion in IDH-mutant astrocytoma.
Journal: Neuro-oncology advances
Published: July 24, 2025
Similar Doctors
Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Voichita Bar Ad
Radiation Oncology
Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Voichita Bar Ad
Radiation Oncology

Jefferson University Physicians

111 S 11th St, 1st Flr Bodine Ctr, 
Philadelphia, PA 
 (0.1 miles away)
215-955-6702
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Voichita Bar Ad is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Bar Ad is rated as a Distinguished provider by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). Her top areas of expertise are Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, Atypical Teratoid Rhabdoid Tumor (ATRT), Neuroepithelioma, and Gamma Knife Radiosurgery.

Experienced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Justin M. Mann
Radiation Oncology
Experienced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Justin M. Mann
Radiation Oncology

Radiation Oncology PC

2 Cooper Plz, 
Camden, NJ 
 (2.4 miles away)
856-342-2300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Justin Mann is a Radiation Oncologist in Camden, New Jersey. Dr. Mann is rated as a Distinguished provider by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). His top areas of expertise are Posterior Fossa Tumor, Astrocytoma, Familial Prostate Cancer, and Glioblastoma.

Experienced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Varsha K. Jain
Radiation Oncology
Experienced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Dr. Varsha K. Jain
Radiation Oncology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (0.1 miles away)
215-955-8874
Experience:
9+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Varsha Jain is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Jain has been practicing medicine for over 9 years and is rated as an Advanced provider by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). Her top areas of expertise are Nasopharyngeal Carcinoma, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Small Cell Lung Cancer (SCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shi's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 13 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile